Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingAutologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer

Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingReduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients

A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingA Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingA Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingAB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205

TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingTACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingSequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant

A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingA Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy

• Post author:
• Post published:October 14, 2026
• Post category:

Continue ReadingPhase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy

Phase I Treatment of Urethral Strictures in Humans

• Post author:
• Post published:October 14, 2026
• Post category:

When a scar, or stricture, forms along the urethra it impedes the flow of urine and causes other complications. James Yoo, M.D., Ph.D., and his team at Wake Forest University…

Continue ReadingPhase I Treatment of Urethral Strictures in Humans